Kymera Investments vs Other Non Cash Items Analysis

KYMR Stock

USD 34.57 0.31 0.90%

Kymera Therapeutics financial indicator trend analysis is infinitely more than just investigating Kymera Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kymera Therapeutics is a good investment. Please check the relationship between Kymera Therapeutics Investments and its Other Non Cash Items accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.

Investments vs Other Non Cash Items

Investments vs Other Non Cash Items Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kymera Therapeutics Investments account and Other Non Cash Items. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Kymera Therapeutics' Investments and Other Non Cash Items is -0.31. Overlapping area represents the amount of variation of Investments that can explain the historical movement of Other Non Cash Items in the same time period over historical financial statements of Kymera Therapeutics, assuming nothing else is changed. The correlation between historical values of Kymera Therapeutics' Investments and Other Non Cash Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Investments of Kymera Therapeutics are associated (or correlated) with its Other Non Cash Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Non Cash Items has no effect on the direction of Investments i.e., Kymera Therapeutics' Investments and Other Non Cash Items go up and down completely randomly.

Correlation Coefficient

-0.31

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Investments

Securities or assets acquired for generating income or appreciating in value, not used in daily operations.

Other Non Cash Items

Most indicators from Kymera Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kymera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kymera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Kymera Stock, please use our How to Invest in Kymera Therapeutics guide.As of 06/12/2024, Sales General And Administrative To Revenue is likely to grow to 1.19, while Selling General Administrative is likely to drop slightly above 30.3 M.

	2021	2022	2023	2024 (projected)
Interest Expense	175K	176K	196K	132.7K
Depreciation And Amortization	488K	6.6M	3.6M	2.5M

Interest Expense Depreciation And Amortization

Kymera Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.66	-0.05	0.94	0.99	0.81	0.95	0.57	0.79	0.5	-0.84	0.88	0.54	0.74	-0.57	0.89	0.98	0.55	0.78	-0.2	0.66	0.97	0.83	0.72	0.99	0.67
Short Long Term Debt Total	0.66		0.52	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13	1.0	0.73	0.79	0.69	0.6	1.0
Other Current Liab	-0.05	0.52		-0.21	-0.04	-0.4	0.18	0.6	-0.54	-0.26	-0.43	0.19	0.61	-0.01	0.12	0.4	-0.17	0.6	0.44	0.01	0.52	0.12	0.47	-0.11	-0.04	0.54
Total Current Liabilities	0.94	0.64	-0.21		0.89	0.94	0.87	0.55	0.91	0.65	-0.72	0.85	0.43	0.82	-0.38	0.76	0.93	0.5	0.65	-0.02	0.64	0.88	0.65	0.86	0.89	0.64
Total Stockholder Equity	0.99	0.6	-0.04	0.89		0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.85	0.59	1.0	0.62
Other Liab	0.81	0.54	-0.4	0.94	0.72		0.7	0.44	0.96	0.64	-0.56	0.74	0.29	0.83	-0.2	0.56	0.82	0.38	0.47	0.18	0.54	0.69	0.42	0.91	0.72	0.52
Net Tangible Assets	0.95	0.8	0.18	0.87	0.95	0.7		0.74	0.68	0.53	-0.94	0.89	0.6	0.79	-0.46	0.96	0.92	0.74	0.79	-0.28	0.8	0.96	0.93	0.64	0.95	0.82
Property Plant And Equipment Net	0.57	0.99	0.6	0.55	0.52	0.44	0.74		0.28	0.43	-0.88	0.8	0.79	0.79	0.14	0.8	0.46	0.99	0.68	0.14	0.99	0.66	0.76	0.62	0.52	0.99
Current Deferred Revenue	0.79	0.38	-0.54	0.91	0.74	0.96	0.68	0.28		0.69	-0.46	0.61	0.07	0.74	-0.31	0.5	0.84	0.25	0.34	-0.06	0.38	0.65	0.38	0.76	0.74	0.37
Net Debt	0.5	0.47	-0.26	0.65	0.46	0.64	0.53	0.43	0.69		-0.38	0.51	0.0	0.78	0.23	0.32	0.47	0.47	0.01	-0.18	0.47	0.45	0.27	0.49	0.46	0.46
Retained Earnings	-0.84	-0.91	-0.43	-0.72	-0.83	-0.56	-0.94	-0.88	-0.46	-0.38		-0.9	-0.79	-0.77	0.32	-0.97	-0.76	-0.88	-0.85	0.13	-0.91	-0.91	-0.95	-0.61	-0.83	-0.93
Accounts Payable	0.88	0.86	0.19	0.85	0.83	0.74	0.89	0.8	0.61	0.51	-0.9		0.8	0.85	-0.22	0.86	0.79	0.78	0.82	0.11	0.86	0.93	0.79	0.81	0.83	0.86
Cash	0.54	0.8	0.61	0.43	0.49	0.29	0.6	0.79	0.07	0.0	-0.79	0.8		0.5	-0.11	0.74	0.4	0.75	0.87	0.34	0.8	0.67	0.69	0.57	0.49	0.8
Non Current Assets Total	0.74	0.84	-0.01	0.82	0.66	0.83	0.79	0.79	0.74	0.78	-0.77	0.85	0.5		0.11	0.68	0.68	0.78	0.47	0.12	0.84	0.72	0.58	0.82	0.66	0.82
Non Currrent Assets Other	-0.57	0.06	0.12	-0.38	-0.65	-0.2	-0.46	0.14	-0.31	0.23	0.32	-0.22	-0.11	0.11		-0.48	-0.65	0.15	-0.54	0.5	0.06	-0.54	-0.52	-0.04	-0.65	0.02
Other Assets	0.89	0.84	0.4	0.76	0.88	0.56	0.96	0.8	0.5	0.32	-0.97	0.86	0.74	0.68	-0.48		0.83	0.78	0.9	-0.2	0.84	0.93	0.98	0.6	0.88	0.86
Cash And Short Term Investments	0.98	0.55	-0.17	0.93	0.98	0.82	0.92	0.46	0.84	0.47	-0.76	0.79	0.4	0.68	-0.65	0.83		0.43	0.72	-0.27	0.55	0.93	0.78	0.68	0.98	0.57
Net Receivables	0.55	0.97	0.6	0.5	0.51	0.38	0.74	0.99	0.25	0.47	-0.88	0.78	0.75	0.78	0.15	0.78	0.43		0.61	0.04	0.97	0.64	0.76	0.53	0.51	0.98
Common Stock Shares Outstanding	0.78	0.72	0.44	0.65	0.76	0.47	0.79	0.68	0.34	0.01	-0.85	0.82	0.87	0.47	-0.54	0.9	0.72	0.61		0.07	0.72	0.84	0.85	0.62	0.76	0.73
Non Current Liabilities Total	-0.2	0.13	0.01	-0.02	-0.35	0.18	-0.28	0.14	-0.06	-0.18	0.13	0.11	0.34	0.12	0.5	-0.2	-0.27	0.04	0.07		0.13	-0.21	-0.36	0.48	-0.35	0.08
Capital Lease Obligations	0.66	1.0	0.52	0.64	0.6	0.54	0.8	0.99	0.38	0.47	-0.91	0.86	0.8	0.84	0.06	0.84	0.55	0.97	0.72	0.13		0.73	0.79	0.69	0.6	1.0
Other Current Assets	0.97	0.73	0.12	0.88	0.97	0.69	0.96	0.66	0.65	0.45	-0.91	0.93	0.67	0.72	-0.54	0.93	0.93	0.64	0.84	-0.21	0.73		0.89	0.65	0.97	0.75
Other Stockholder Equity	0.83	0.79	0.47	0.65	0.85	0.42	0.93	0.76	0.38	0.27	-0.95	0.79	0.69	0.58	-0.52	0.98	0.78	0.76	0.85	-0.36	0.79	0.89		0.43	0.85	0.82
Total Liab	0.72	0.69	-0.11	0.86	0.59	0.91	0.64	0.62	0.76	0.49	-0.61	0.81	0.57	0.82	-0.04	0.6	0.68	0.53	0.62	0.48	0.69	0.65	0.43		0.59	0.66
Net Invested Capital	0.99	0.6	-0.04	0.89	1.0	0.72	0.95	0.52	0.74	0.46	-0.83	0.83	0.49	0.66	-0.65	0.88	0.98	0.51	0.76	-0.35	0.6	0.97	0.85	0.59		0.62
Property Plant And Equipment Gross	0.67	1.0	0.54	0.64	0.62	0.52	0.82	0.99	0.37	0.46	-0.93	0.86	0.8	0.82	0.02	0.86	0.57	0.98	0.73	0.08	1.0	0.75	0.82	0.66	0.62

Click cells to compare fundamentals

Kymera Therapeutics Account Relationship Matchups

Kymera Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Short Long Term Debt Total	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Liab	4.6M	(67.4M)	(7.6M)	(8.3M)	34.4M	36.1M
Total Current Liabilities	34.6M	110.6M	101.0M	63.3M	85.7M	73.3M
Total Stockholder Equity	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Other Liab	29.6M	77.9M	39.4M	28.2M	32.5M	38.6M
Net Tangible Assets	(74.4M)	283.9M	459.6M	490.2M	563.7M	591.9M
Property Plant And Equipment Net	22.1M	10.8M	11.9M	13.3M	101.1M	106.1M
Current Deferred Revenue	23.3M	170.4M	101.0M	63.3M	37.9M	73.0M
Net Debt	(54.8M)	(13.0M)	(30.0M)	(51.1M)	(25.3M)	(26.6M)
Retained Earnings	(76.5M)	(128.8M)	(229.0M)	(383.8M)	(530.8M)	(504.2M)
Accounts Payable	3.3M	4.4M	4.0M	4.3M	7.1M	4.6M
Cash	76.0M	31.0M	48.0M	68.4M	110.0M	68.7M
Non Current Assets Total	23.9M	184.8M	38.3M	43.6M	170.4M	179.0M
Non Currrent Assets Other	1.8M	11.5M	(98.8M)	(122.0M)	7.9M	8.3M
Other Assets	1.8M	1.6M	8.1M	9.1M	10.5M	11.0M
Cash And Short Term Investments	92.0M	458.7M	567.6M	559.5M	374.9M	383.9M
Net Receivables	287K	1.4M	135K	2.5M	18.8M	19.7M
Common Stock Shares Outstanding	44.5M	17.3M	48.0M	53.9M	58.4M	44.4M
Short Term Investments	15.9M	265.2M	394.4M	338.8M	264.9M	234.5M
Liabilities And Stockholders Equity	116.7M	487.2M	605.9M	603.1M	575.8M	446.0M
Non Current Liabilities Total	156.5M	92.7M	45.2M	49.7M	95.1M	68.4M
Capital Lease Obligations	21.2M	18.0M	18.0M	17.3M	84.7M	88.9M
Other Current Assets	888K	5.6M	8.9M	9.7M	11.7M	6.8M
Other Stockholder Equity	(107.0M)	(74.4M)	689.3M	878.9M	926.3M	972.6M
Total Liab	191.1M	203.3M	146.3M	113.0M	180.8M	167.4M
Net Invested Capital	(74.4M)	283.9M	459.6M	490.2M	395.0M	278.6M
Property Plant And Equipment Gross	22.1M	20.7M	25.2M	29.1M	111.5M	117.1M
Total Current Assets	92.8M	302.3M	567.6M	559.5M	405.3M	361.1M
Accumulated Other Comprehensive Income	6K	(128K)	(660K)	(4.9M)	(552K)	(579.6K)
Net Working Capital	58.3M	191.7M	358.7M	348.1M	319.6M	240.8M
Short Term Debt	3.4M	3.3M	3.6M	3.9M	6.3M	3.8M
Property Plant Equipment	22.1M	20.7M	11.9M	13.3M	15.3M	15.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Kymera Stock Analysis

When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kymera Investments vs Other Non Cash Items Analysis

Investments vs Other Non Cash Items

Investments vs Other Non Cash Items Correlation Analysis

Correlation Coefficient

Investments

Other Non Cash Items

Kymera Therapeutics fundamental ratios Correlations

Kymera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kymera Therapeutics fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for Kymera Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 1.0	Short Long Term Debt Total
Net Invested Capital	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Capital Lease Obligations
Total Stockholder Equity	+ 0.99	Total Assets
Net Invested Capital	+ 0.99	Total Assets

Other Assets	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.95	Retained Earnings
Retained Earnings	- 0.94	Net Tangible Assets
Property Plant And Equipment Gross	- 0.93	Retained Earnings
Other Current Assets	- 0.91	Retained Earnings
Capital Lease Obligations	- 0.91	Retained Earnings